UNSPSC 51281665: Sisomicin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula 2C19H37N5O7.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K14444371C, chemically known as o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-l-streptamine sulfate (2:5) (salt) but more generally known as sisomicin sulfate, which bears US NIH Compound Identifier 65334.

UNSPSC 51281665 Sisomicin sulfate (Commodity) encompasses pharmaceutical active pharmaceutical ingredients and finished-dose medications that state and local health departments and county agencies procure for public health programs, emergency response stockpiles, and community health initiatives. Recent solicitations show state and local governments buying antibiotics, opioid-reversal agents, and drug-disposal systems through piggyback contracts leveraging multi-jurisdictional purchasing cooperatives and direct competitive bidding. The code reflects actual procurement activity in pharmaceutical supply chain management rather than narrow chemical sourcing alone.

Activity under the code appears sparse in recent public records. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC (Bid Number 26-482DPH-PREPD-B-53392, August 28, 2026) for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 over three years. Seminole County, Florida issued an IFB for Naloxone and Safe Drug Deactivation Systems (IFB 60459723LAS, posted June 30, 2026) requiring 1,900 units of Naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. Recent opportunities cluster in Florida and Illinois, with procurement vehicles including cooperative purchasing agreements and county-level competitive bids. Neither opportunity specifically targets sisomicin sulfate; the code shows limited direct recent solicitation activity at the state and local level.